Nectar Lifesciences shifts toward real estate after debt clearance

Nectar Lifesciences Limited says it has discharged all debt after selling a substantial part of its former operations and is evaluating real-estate projects, with Rs 112.2477 crore of standalone cash and cash equivalents at September 30, 2026. The company has also acquired Avensis Exports Private Limited as a wholly owned subsidiary in furtherance of the revised objective.

What businesses and assets has Nectar Lifesciences sold or put up for sale?

Nectar Lifesciences sold a substantial part of its existing operations through a slump sale during the previous financial year, according to its November 14, 2026 results filing. The company says this transaction created significant liquidity and enabled debt discharge, although the filing does not specify the consideration or identify the precise operations covered by that earlier sale.

Nectar Lifesciences also entered into a Business Transfer Agreement on December 20, 2025, to sell its Empty Hard Gelatin Capsule business to Capnest Health Care Private Limited. The proposed consideration is Rs 19.90 crore, including related receivables and payables or creditors, subject to specified working-capital adjustments and approval under Section 118 of the Himachal Pradesh Tenancy and Land Reforms Act, 1972.

The capsule business transfer had not been reported as completed as of September 30, 2026. Nectar Lifesciences classified the related assets as held for sale and said completion will occur under the agreement's terms. Fixed assets at its Jammu unit, which had remained inoperative, were disposed of during the half year ended September 30, 2026.

Why is Nectar Lifesciences evaluating real-estate projects?

Nectar Lifesciences amended its object clause to undertake activities in the real-estate sector and is evaluating projects under a revised business framework. The November 2026 filing does not identify a project, location, investment amount, development timetable, counterparty or prospective revenue, meaning the disclosed activity remains at an evaluation stage.

Nectar Lifesciences acquired Avensis Exports Private Limited, referred to in the filing as AEPL, as a wholly owned subsidiary to further the real-estate objective. AEPL is one of two wholly owned subsidiaries at September 30, 2026, while Neclife PT, Unipessoal LDA remained inoperative during the period. The filing does not state AEPL's asset base, project role or planned capital commitment.

The company still described itself as exclusively in the pharmaceutical business segment in its September 2026 financial-results notes. This differs from its amended object clause, but the filing does not disclose a separate real-estate operating segment or real-estate revenue for the quarter or half year ended September 30, 2026.

What do Nectar Lifesciences' September 2026 results show?

Nectar Lifesciences reported standalone total income from continuing operations of Rs 17.04 crore for the quarter ended September 30, 2026, compared with Rs 6.29 crore in the quarter ended June 30, 2026, and Rs 74.07 lakh a year earlier. Other income accounted for Rs 17.02 crore of the September-quarter total, while income from operations sales was Rs 1.10 lakh.

Standalone continuing operations made a profit after tax of Rs 5.78 crore in the September quarter, reversing a Rs 13.46 crore loss in the June quarter. Total expenses declined to Rs 6.76 crore from Rs 27.95 crore over the two quarters, while other income increased from Rs 5.85 crore to Rs 17.02 crore.

For the half year ended September 30, 2026, continuing operations recorded a standalone loss after tax of Rs 7.67 crore, against a restated profit of Rs 39.03 lakh in the prior-year half. Other expenses were Rs 32.42 crore, compared with Rs 21.14 lakh a year earlier, while the period included a deferred-tax credit of Rs 3.71 crore.

Discontinued operations reduced the standalone half-year outcome by another Rs 51.86 lakh after tax. Capsule-business revenue was Rs 7.35 crore for the six months ended September 30, 2026, down from Rs 373.94 crore in the restated comparable period, while its loss before tax narrowed to Rs 79.72 lakh from Rs 367.88 crore.

How much liquidity and debt does Nectar Lifesciences report?

Nectar Lifesciences says it discharged all debts and has adequate cash and liquid resources to meet its obligations. Its standalone balance sheet reported no current or non-current borrowings at September 30, 2026, while cash and cash equivalents were Rs 112.2477 crore, up from Rs 108.1304 crore at March 31, 2026.

Standalone current investments rose to Rs 55.5126 crore at September 30, 2026, from Rs 12.9708 crore at March 31, 2026. Total current assets were Rs 237.8925 crore, down from Rs 249.5681 crore, while total current liabilities declined to Rs 20.2040 crore from Rs 25.9670 crore over the same period.

The standalone cash-flow statement recorded Rs 46.0624 crore of operating cash inflow for the half year ended September 30, 2026, compared with Rs 152.6848 crore in the restated prior-year half. Net cash used in investing activities was Rs 40.8718 crore, including Rs 879.8934 crore of investment purchases and Rs 810.6265 crore of investment sales.

Cash proceeds from assets held for sale were Rs 22.3325 crore in the six months to September 30, 2026. Net cash generated from financing activities was negative Rs 15.83 lakh, compared with negative Rs 157.7219 crore in the prior-year half, when the statement recorded repayments of bank term loans and working-capital limits.

What unresolved matters remain in Nectar Lifesciences' transition?

Nectar Lifesciences recognised a Rs 26.7250 crore loss on the sale and restatement of investments for the half year ended September 30, 2026. Management attributed the loss to market volatility affecting mutual funds, exchange-traded funds and equity instruments amid market conditions and geopolitical developments; Rs 25.1329 crore of the loss had been incurred up to June 30, 2026.

The company is also evaluating the monetisation of vacant land near Garhshankar, Punjab, to optimise non-core assets and strengthen liquidity. A portion of the land was sold during the September 2026 quarter, and management expects the balance to be sold by the end of the financial year, but the filing provides no consideration or carrying value.

Standalone non-current assets classified as held for sale were Rs 27.5888 crore at September 30, 2026, down from Rs 35.8539 crore at March 31, 2026. Liabilities directly associated with assets held for sale fell to Rs 2.2996 crore from Rs 4.0642 crore, showing that disposal activity remained part of the company's position at the half-year date.

Conclusion

Nectar Lifesciences is repositioning after a substantial slump sale, debt discharge and further asset disposals, but its new real-estate direction has not yet produced disclosed operating revenue. The Rs 5.78 crore September-quarter continuing profit depended largely on Rs 17.02 crore of other income, while the half-year continuing loss was Rs 7.67 crore and investment losses totalled Rs 26.7250 crore.

The next disclosed milestones are completion of the proposed Rs 19.90 crore capsule-business transfer and management's expectation that the remaining Garhshankar land will be sold by the end of the financial year. Investors will also be watching for specific project, funding or timetable disclosures for the real-estate activities being evaluated directly or through AEPL.